Patents by Inventor Gemma Liwicki

Gemma Liwicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions
    Patent number: 11465994
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: October 11, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Martin Teall, Kathryn White, Stephen Mack, Gemma Liwicki, Anne Stephenson, Louise Dickson
  • MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS
    Publication number: 20190345148
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 14, 2019
    Inventors: Martin Teall, Kathryn White, Stephen Mack, Gemma Liwicki, Anne Stephenson, Louise Dickson
  • INDANE DERIVATIVES AS MGLUR7 MODULATORS
    Publication number: 20190031599
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 31, 2019
    Inventors: Anne Goldby, Gemma Liwicki, Stephen Mack, Martin Teall, Katy White